METANOIA-COMMUNICATIONS
2.3.2020 05:21:10 CET | Business Wire | Press release
Metanoia Communications Inc. (Metanoia), a leading manufacturer of standalone high-speed xDSL and Gfast PHY chipsets for the wireline broadband market, is excited to announce that it has successfully completed its most significant fundraising in the history of the company from a stellar consortium of domestic investors led by Taiwania Capital Investment and National Development Fund. Elan Microelectronics, the original primary investor in Metanoia, is also participating in this new round of investment.
“Introduction of new and innovative products is a key area of focus in Metanoia’s strategy and this new round of investment will enable Metanoia to develop and release 5G chips for Remote Radio Units (RRU), Small Cells and CPEs in near future,” said Chien-Te Wu, Metanoia President & CEO. “The company will further capitalize on and broaden its established position as a recognized leader in the Broadband Wireline markets, where our employees are striving to enhance the overall customer experience, while deepening relationships with existing and new customers.”
Taiwania Capital CEO David Weng added: “Taiwania Capital Investment is very excited about investing in Metanoia as it embarks on a new journey with its strategic decision to diversify into the 5G market with the introduction of exciting new products with significant potential and market prospects.”
The funding will also be used to support the launch of Metanoia’s new Gfast / VDSL2 family of chipsets and is also expected to drive further international adoption and expansion.
5G solutions are rapidly moving beyond just providing indoor coverage within buildings or arenas, and are becoming strategic enablers of outdoor network densification for Services Providers and will be the key components in strengthening the Service Providers’ 5G deployments. Building chips that can serve both RRU and Small Cell markets as well as the CPE is an important element of Metanoia’s product strategy to meet these requirements.
“By developing our innovative and highly programmable architecture for our Broadband Wireline products, and by leveraging our partners’ knowledge in 5G technology, Metanoia quickly realized that it could adapt and use existing technology and apply it to certain 5G market segments,” added Didier Boivin, Metanoia executive vice president. “While the medium is different than what Metanoia has previously served, (wireless vs. wireline), there are significant overlaps at the physical layer (PHY) enabling Metanoia to leverage its existing technology and quickly come up with new 5G products and enable our current and future customers to meet the market requirements.”
“Taiwan is embarking on a strategy and plan for deploying 5G in both public and private enterprise networks in 2020. Key goals in Taiwan’s 5G program include providing end-end solutions in enterprise network for vertical applications and obtaining significant market shares for 5G related products,” said Dr. Li Fung Chang, CTO, 5G Technology Program Office, Ministry of Economic Affairs(MoEA). “To achieve these goals, it is counting on its domestic enterprises to contribute to the success of the program. Several companies are already enlisted from server companies to chipset companies like Metanoia. Upcoming new 5G products from Metanoia will bring the flexibility needed to implement features which could be helpful in quickly adapting to the changing market requirements and thereby creating lasting differentiators to the market.”
Metanoia will next participate at COMPUTEX 40th in Taipei, Taiwan from June 2nd to June 6th 2020.
Please come to visit us.
About Metanoia Communications, Inc.
Metanoia Communications, a subsidiary of Elan Microelectronics, was established in Hsinchu Science Park, Taiwan. Since its inception, Metanoia has been contributing to the development of several generations of semiconductor and software solutions for the wireline Broadband and the in-home networking markets, delivering to broadband manufacturers very high-speed PHY devices with reliable and superior performances.
For more information about Metanoia, please visit our website at www.metanoia-comm.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200301005079/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom